{"ticker": {"uuid": "21d886d0-3ec1-4e92-88dd-fbaf7243a15f", "symbol": "PTGX", "name": "Protagonist Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com", "summary": "Protagonist Therapeutics (PTGX) stock reached an all-time high of $141.79, currently trading at $143.26 with a market capitalization of $9.06 billion. The company has seen significant growth, with a 155.18% increase over the past year and a 61% year-to-date return, driven by posi", "url": "https://ca.investing.com/news/stock-market-news/protagonist-therapeutics-stock-hits-alltime-high-at-14179-usd-93CH-4742066", "source_name": "Investing.com Canada", "published_at": "2026-07-20T13:39:44", "published_display": "20 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Barclays 28th Annual Global Healthcare Conference summary", "summary": "Protagonist Therapeutics (PTGX) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting its focus on novel peptide therapeutics and its two lead assets, icotrokinra and rusfertide. Icotrokinra, an oral IL-23 blocker, targets psoriasis, while rusfertide, a", "url": "https://quartr.com/events/protagonist-therapeutics-ptgx-barclays-28th-annual-global-healthcare-conference_FLI9Rqt9", "source_name": "Quartr", "published_at": "2026-07-20T10:39:44", "published_display": "20 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T12:31:41+00:00", "published_display": "19 Jul 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally", "summary": "Protagonist Therapeutics saw its shares surge 5.7% on Friday, closing at $139.60, as the biotech company benefited from a broad sector-wide rally. This synchronized movement among biotechnology stocks suggests that macro factors and a shift in investor risk appetite, rather than ", "url": "https://news.alphastreet.com/protagonist-therapeutics-jumps-5-7-amid-sector-wide-rally/", "source_name": "AlphaStreet", "published_at": "2026-07-17T17:10:57", "published_display": "17 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Reports Granting of Inducement Awards", "summary": "Protagonist Therapeutics granted inducement awards to three new employees, consisting of options to purchase 12,600 shares and RSUs for 3,330 shares of common stock. These awards were made under its Amended and Restated Inducement Plan, with vesting periods of four years for both", "url": "https://finance.yahoo.com/healthcare/articles/protagonist-therapeutics-reports-granting-inducement-200500825.html", "source_name": "Market source", "published_at": "2026-07-17T11:09:52", "published_display": "17 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens raises Protagonist Therapeutics price target on Icotyde uptake By Investing.com", "summary": "Citizens increased its price target for Protagonist Therapeutics (NASDAQ: PTGX) to $165 from $137, while maintaining a Market Outperform rating, due to better-than-expected prescription volume for its drug Icotyde. The firm now estimates approximately $8 million in second-quarter", "url": "https://ca.investing.com/news/stock-market-news/citizens-raises-protagonist-therapeutics-price-target-on-icotyde-uptake-93CH-4739233", "source_name": "Investing.com Canada", "published_at": "2026-07-17T09:58:20", "published_display": "17 Jul 2026 09:58", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three New Hires Receive Protagonist Options and RSUs Under Inducement Plan", "summary": "Protagonist Therapeutics (Nasdaq: PTGX) granted equity inducement awards to three new employees on July 15, 2026. These awards include options for 12,600 shares and RSUs for 3,330 shares, with an option exercise price of $135.46. The awards were approved by the compensation commi", "url": "https://www.stocktitan.net/news/PTGX/protagonist-therapeutics-reports-granting-of-inducement-dcke3ikg6f1p.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:11:19", "published_display": "16 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight", "summary": "Protagonist Therapeutics saw its shares jump 5.3% to $138.27 after Barclays maintained an Overweight rating and significantly raised its price target by 26.9% to $151. This upgrade reflects increasing confidence in the biotechnology company's prospects, driving keen investor inte", "url": "https://news.alphastreet.com/protagonist-therapeutics-jumps-5-3-after-barclays-maintains-overweight/", "source_name": "AlphaStreet", "published_at": "2026-07-16T10:39:59", "published_display": "16 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX Maintained by Barclays -- Price Target Raised to $151", "summary": "Barclays has maintained an \"Overweight\" rating for Protagonist Therapeutics (PTGX) and increased its price target from $119.00 to $151.00, signaling confidence in the company's biotech potential. While analysts are optimistic, GuruFocus indicates that PTGX is significantly overva", "url": "https://www.gurufocus.com/news/8957467/ptgx-maintained-by-barclays-price-target-raised-to-151", "source_name": "GuruFocus", "published_at": "2026-07-14T12:39:48", "published_display": "14 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Protagonist Therapeutics (PTGX) AGM 2026 Summary", "summary": "This article summarizes Protagonist Therapeutics' (PTGX) 2026 Annual General Meeting (AGM). Key topics included the election of directors, an advisory vote on executive compensation, ratification of the auditor (Ernst & Young), and approval of the 2026 equity incentive plan. The ", "url": "https://quartr.com/events/protagonist-therapeutics-inc-ptgx-agm-2026_FLI9TJSQ", "source_name": "Quartr", "published_at": "2026-07-11T09:12:12", "published_display": "11 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Investor Update Summary", "summary": "Protagonist Therapeutics (PTGX) announced positive phase III VERIFY study results for Rusfertide in polycythemia vera, meeting primary and secondary endpoints with significant efficacy and improved patient-reported outcomes. The drug was well-tolerated with no new safety signals.", "url": "https://quartr.com/events/protagonist-therapeutics-inc-ptgx-investor-update_FLI94zCp", "source_name": "Quartr", "published_at": "2026-07-11T09:10:21", "published_display": "11 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "This article summarizes Protagonist Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. The company is transitioning to a commercial stage, anticipating approval for Rusfertide, and boasts a strong financial position due to product la", "url": "https://quartr.com/events/protagonist-therapeutics-inc-ptgx-goldman-sachs-47th-annual-global-healthcare-conference-20_FLI9TQMC", "source_name": "Quartr", "published_at": "2026-07-11T08:39:38", "published_display": "11 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Icotyde\u2019s Launch and Rusfertide\u2019s Priority Review Change Protagonist Therapeutics\u2019 (PTGX) Narrative", "summary": "Protagonist Therapeutics (PTGX) has experienced a significant shift in its investment narrative due to the U.S. launch of its psoriasis drug Icotyde and the FDA priority review for its polycythemia vera candidate rusfertide, with an action date in August 2026. This marks a transi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/will-icotydes-launch-and-rusfertides-priority-review-change", "source_name": "Simply Wall Street", "published_at": "2026-07-10T21:10:14", "published_display": "10 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/protagonist-therapeutics-ptgx-icotyde-launch-141440105.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T14:14:40+00:00", "published_display": "09 Jul 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNjYyazduVzM5SzR4TkdoWVRfb1BnLWhVWFVfNC1DWGthNmZzNHczbjluZ0JKbmRHZGRXTFhsamxDaVR6c0dQa3FuWVFmZTludHkyMzEzMU5YSXhGSjV1WEFsOG1ERHY5RnBsQnVxN0dQLTlKNkFMMXFRSjlBVVRUVXEwZG5JUDRuekcydWFYNnp4S3VCMllxWGhkUkI2RVJDSFIxWHloSlV0QQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest", "summary": "Protagonist Therapeutics (PTGX) saw its stock climb 7.1% due to investor focus on key pipeline milestones and recent FDA activity related to rusfertide and Icotyde. Despite a P/B ratio of 13.7x, which is high compared to the broader US biotech sector, a discounted cash flow (DCF)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-could-be-66-below-fair-value-a", "source_name": "Simply Wall Street", "published_at": "2026-07-09T07:41:46", "published_display": "09 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Q1 2026 earnings summary", "summary": "Protagonist Therapeutics reported a strong Q1 2026 driven by FDA approval for ICOTYDE, triggering a $50M milestone payment, and a strategic opt-out of U.S. profit-sharing for rusfertide with Takeda, resulting in a $200M payment. The company achieved significant revenue growth and", "url": "https://quartr.com/events/protagonist-therapeutics-inc-ptgx-q1-2026_FLI9RqxP", "source_name": "Quartr", "published_at": "2026-07-08T20:10:21", "published_display": "08 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/protagonist-therapeutics-ptgx-12-5-161823936.html", "source_name": "Simply Wall St.", "published_at": "2026-07-08T16:18:23+00:00", "published_display": "08 Jul 2026 16:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?", "summary": "Protagonist Therapeutics (PTGX) stock saw a significant 7.1% rally, closing at $140.85, driven by investor confidence in its late-stage drug candidate rusfertide and expanding commercial opportunities for Icotyde. The FDA has accepted a new drug application for rusfertide with pr", "url": "https://finance.yahoo.com/markets/stocks/articles/protagonist-therapeutics-ptgx-surges-7-143000071.html", "source_name": "Market source", "published_at": "2026-07-08T10:30:00", "published_display": "08 Jul 2026 10:30", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com", "summary": "Truist Securities has increased its price target for Protagonist Therapeutics Inc. (NASDAQ: PTGX) to $145 from $121, maintaining a Buy rating, based on the strong commercial potential of its drug Icotyde. Johnson & Johnson, Protagonist's commercial partner, has highlighted Icotyd", "url": "https://ng.investing.com/news/stock-market-news/truist-raises-protagonist-therapeutics-stock-price-target-on-icotyde-outlook-93CH-2588523", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T19:42:01", "published_display": "07 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX Stock Grinds Higher As Pipeline Catalysts Build", "summary": "Protagonist Therapeutics (PTGX) stock rose over 7% following positive drug development news. The company launched ICOTYDE in the U.S. for psoriasis and has rusfertide under FDA priority review for polycythemia vera, alongside ongoing Phase 3 trials for ICOTYDE in other inflammato", "url": "https://stockstotrade.com/news/protagonist-therapeutics-inc-ptgx-news-2026_07_07/", "source_name": "StocksToTrade", "published_at": "2026-07-07T19:40:17", "published_display": "07 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies", "summary": "Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for inflammatory and hematologic diseases. The Nasdaq-listed company aims to advance its multi-program pipeline through clinical trials, differentiating its", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/protagonist-therapeutics-updates-its-clinical-pipeline-ptgx-focuses-on/69716334", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:11:28", "published_display": "07 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally", "summary": "Protagonist Therapeutics (PTGX) saw its shares rise by 5.2% on Tuesday, closing at $138.29, due to a broad rally across the biotechnology sector. This increase was part of a coordinated move, with several peer companies also experiencing similar gains, suggesting a sector-wide mo", "url": "https://news.alphastreet.com/protagonist-therapeutics-jumps-5-2-amid-sector-wide-rally/amp/", "source_name": "AlphaStreet", "published_at": "2026-07-07T16:40:17", "published_display": "07 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?", "summary": "Protagonist Therapeutics (PTGX) stock has surged 64% in the last six months, driven by progress in its rare hematology candidate rusfertide, the commercial expansion of its immunology therapy Icotyde, and advancements in its pipeline assets. The FDA's priority review of rusfertid", "url": "https://www.tradingview.com/news/zacks:891a6064e094b:0-ptgx-stock-surges-64-in-six-months-what-is-driving-the-rally/", "source_name": "TradingView", "published_at": "2026-07-07T15:11:28", "published_display": "07 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX Maintained by Truist Securities -- Price Target Raised to $145.00", "summary": "Truist Securities has reiterated a 'Buy' rating for Protagonist Therapeutics (PTGX), increasing the price target from $121.00 to $145.00, indicating optimism about its pipeline. Despite this, GuruFocus assesses PTGX as 114.6% overvalued with a GF Value\u2122 of $61.27, and its GF Scor", "url": "https://www.gurufocus.com/news/8947303/ptgx-maintained-by-truist-securities-price-target-raised-to-14500", "source_name": "GuruFocus", "published_at": "2026-07-07T13:11:28", "published_display": "07 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Protagonist Therapeutics, Inc. \u2013 NASDAQ:PTGX", "summary": "This article provides financial data for Protagonist Therapeutics, Inc. (NASDAQ: PTGX), specifically focusing on its forward price-to-sales ratio. It lists the company's ticker, stock market, and highlights its current financial and market status.", "url": "https://www.tradingview.com/symbols/NASDAQ-PTGX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T11:11:28", "published_display": "07 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating", "summary": "Truist has increased its price target for Protagonist Therapeutics (PTGX) to $145 from $121, while maintaining a Buy rating on the stock. This news follows the company's Q4 financial results where Unity Software (U.US) reported significant revenue growth, though the article seems", "url": "https://www.moomoo.com/news/post/72579388/truist-raises-price-target-on-protagonist-therapeutics-to-145-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T10:40:17", "published_display": "07 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist raises Protagonist Therapeutics stock price target on Icotyde outlook", "summary": "Truist Securities has increased its price target for Protagonist Therapeutics (NASDAQ: PTGX) to $145 from $121, maintaining a Buy rating, based on the strong commercial outlook for its drug Icotyde in psoriasis treatment. Johnson & Johnson, Protagonist's commercial partner, proje", "url": "https://www.investing.com/news/analyst-ratings/truist-raises-protagonist-therapeutics-stock-price-target-on-icotyde-outlook-93CH-4778730", "source_name": "Investing.com", "published_at": "2026-07-07T06:52:00", "published_display": "07 Jul 2026 06:52", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Protagonist Therapeutics, Inc. \u2013 NASDAQ:PTGX", "summary": "This article provides financial information for Protagonist Therapeutics, Inc. (NASDAQ: PTGX), specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or a data page from TradingView, displaying the current market status and various navigation optio", "url": "https://www.tradingview.com/symbols/NASDAQ-PTGX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T19:10:11", "published_display": "06 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Protagonist Therapeutics, Inc. \u2013 NASDAQ:PTGX", "summary": "The article provides the enterprise value to revenue forward for Protagonist Therapeutics, Inc. (NASDAQ: PTGX). It presents basic financial and market information for the company as listed on TradingView, covering its Nasdaq Stock Market data.", "url": "https://www.tradingview.com/symbols/NASDAQ-PTGX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T15:43:23", "published_display": "06 Jul 2026 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD", "summary": "Protagonist Therapeutics Inc. (PTGX) stock has reached an all-time high of $131.99, currently trading at $132.27, showcasing a significant 163.93% increase over the past year. Despite analysts viewing the stock as overvalued, they predict profitability this year with forecasted e", "url": "https://www.investing.com/news/company-news/protagonist-therapeutics-inc-stock-hits-alltime-high-at-13199-usd-93CH-4776767", "source_name": "Investing.com", "published_at": "2026-07-06T14:43:23", "published_display": "06 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Protagonist (NASDAQ: PTGX) trades 9,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPNGZ3ZTk3czJ2SlNOcDRReHpuOTZUOHdGLVQ0VWhCU1ZyMVNQLWtxdmJoMEp4cDBfRlhVbE9xdEhLbzlRLTVFVnBJS21PSGNLM05MUGxXb1hpRDQ4UmtTUVU5VHN3eV9EYkJneHA3X0VERWZPSl9xTFVRbUZTd210SDQtWGZGZDRvN2dqX3Z2aUJrbmgtVXhtZy01dms4SEtqNnVJWGJtMENQX0VPbTg0YjdETjVTdzZUYnNNQlZmbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX (NASDAQ) insider 10b5-1 sale of 9,000 shares; option exercise noted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNa3JkT1dkTjBSMjhXMXNlS1VFdDgzQldyZ19HS0dMTDZrcDdkRzZ5bzZRX29qMUpZLWlHX3V5eEhaWVZFTTh4aFh1dl9uLTBKTnVmQk0zdGwyODdkXzJ6SVBYdEJYQTU4eDJBQjAxeExyRHpGTU1OSkZPZHhUTkxVbVFNZW0zTEdQM25STjYtR1JhLWZwSU9JZFFZMTJzbV91Z0Fhb2NVazg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOcGtaYVlZSGVIX2RCNHQ1VTdEazZqYXd0Mjh4cl9ZR0VaYkpSbUM4VEdSTDVaSjh4cDIzbDgweVQxTHMwWmRkNnpyMTAwZWhsbW02bTJjRFhjVWFDZ0FTb29udWstR2pyYlZnS1czdkVsaUdHbXBCQmpaQTNZckNqQngzTURtNXd3al9kMy1XNnQzM29QZHUzQUNZekJ4Q3JidFJiWFJGbGVlUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging Higher", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPTnhibVJ6MElyTnljYk10VUV4ZU1iR0xNdXgtd2oxV3FRc3dVSnJCSVNlZURQYTZQZFRDWFhCcnFleWpkdTV3NW54bVFzNWkyUnFXZXJLbWptMXdTS1ZTZVlnaTlpX3RiWk5senB4WmZRaERTR21odGdUejU5WVdORy1YZnBuck13SUh3clFMQjMyOVg3djVGbm55UlNzVElQNERIdjJra0FoX000R1Z1aw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQZ3pXQWJuY05fWkkyWms5bHNrU3l4MklmTFRIeUQ2UWl5UWk4ZTBWN1lOTGFkd0lEb0hURGpnY20yNk01SnY0bmlVZVFlTHlEelVSNG1ZZE81eTE5VDBEVkg3UGtDOHhmTDk4UUppN253cG5uaWVQLU9QSkx3eWJZYWdOY3VXTEM5NkN0RUFjZGJabEJPU1dqbThMeV9qOE0wWWJHTzJMRm9BM0xpN0ZGSE1OS28tZ05raWZGcWE0Q2xFNXdVRnZlUnVvOHU4am1STncwWHVqSGRlSDE1LTZZWkZBWi1DZmRpdVk2MHFB?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVTB4T19JMS1rejZnbnl5ODVtcEMxR1hwVXlBclUzalk4TGNBQU82bGR5eUNMOWYxS2ltM0RDeFRBWnR6MFZwdjEzQ0dHSUdNajMtN0IzUEJtZWNKdk1rOS1SMEpGYmt6czFIeE5DNUtPWVhWSnBrYTdQaURFQjZ3R20wbElLVlhfa0x2SUJGY2FUZ0VqRTNtbjNFQ1FwTF9kLVpuZVdldlAxWmc?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPa1BaaC1wWk5TZFF4WC1jNi1RdXNfOTVJdkdNbXd4Y2xFejVmYnBZTnhWOVdIa0FwOVRObnBKZE1TMGJURmxOQmNxTVFiZkpHRXhrNHBYQlE2Z29CSFBYaVVQVFJ3aU5YbW5Pdk5ya1ZoZUtnMzlTWjRuSlRzWHpJelpxbU9UWGlyaUhfZDF4WDVWQm1kTVFPMzJrZ1lPQzk4M00wOTEwdHhfMUJaWW5Z?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda takes U.S. rights to rusfertide; Protagonist eligible for $475M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOTUJlTjRJOEFheWVVNkR3QXFXTzNRREtGRkFUUzNtSDk0eTFsTC1wM0Y0Sk1iN0ppTFJWcTNzbWxCMTRMZXl3MG1ma3FxX3BTLWFUb0VjazRlbXR6NUVPVjZlOU42anpRWUFtNXJzWmZJdV8xcDRTWlBNMi1fXzFXSGhSbUh6T1BfLWNJMkxCZ0dXVzN6TlU0UGdBTWtPOU1ITldCblBoaWwxeF96QjJrN1FzS3pVZXI3U1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPTmotR3lfS2V6WEtvWFdwR3RWTG54SHdkUUN6Z0d2VXdfV2JHZEplV2dwT1JteHJVUWJmb1htNDkyamxJNDZOQ3dPX2JoNldSQjJMWV9nMkFFbi1QV3pTMjBiamJwN1JMZ1JrMTItdzZDdGZKYWlGTmc4RmpTZGhhREZfYXpBVzh3NzNIMWdSRUJKc29hTGwtMEZ4dFJCYnR3OS1QMWJmOUw0VnFBRzdrUG9wZlM?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is It Too Late To Consider Protagonist Therapeutics (PTGX) After A 129% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Two new hires get rights to 69,850 Protagonist shares in awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNVVBZNEdZeTdIc2NwdTVRbkhZRF9JM0tteG5WcGpkSFdEOE1UbW1pUEV0MXpRZHJHd2s2VTRXNmg4R19hNlgtYmhLNTkzRXhmazNMeXppUWxtUHl0U1lLYzlwc0FZdG00eWhXbVR5WC1CVzRZeG1wWmR5TzVMWFlqRFBMS2UtZ1dPcHREb1o0NTNwUjIyeVlmbnd3TGlfTjNwUUtNZ3JvOUo3NnpiNHZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPbE5JMFA0WndobVlVZXBUanhGT3ZmdmNzdW1SZ0FSOFM5UXdhN1M4WlJpTk4wMFNmMFRyVm5QQnVySHAweWhMZUFOOHFGUGJuaGFLTTNobjNYTlNSUHN3UFNqaEhoRWhwcHZrNUxjWWFTVFFNeHBseEdxVFhFMGFuN0ZPNy02akFRODU0MlFEcEtNeXB4SXpKbml2SjNyUDMxWHZSTg?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQd0JMT0FRRWs0bFM2aXRmU0ZOQnZNNEJTdS1QTUNEbmd6RUc0a1pkcGtSSE5nN1FQSFZlTHZCZDkzSjZqeFN3cXRTTU5Gd1EzUk9NSXVFTlROVjB4ZlpzdnZQLWlkbU16cFVrSXl3Ynd1anR6cUFsR2NMaVhXSkpNMW56UnM5dnR4ZXE2MC00emhYNU9nbHhiX0Jibk0wdmRnemNmY3M2ZnVmZXFKOF93?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves first oral IL-23 psoriasis pill, Protagonist lands $50M", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZk5kZ19ZbDZ3bHhrWF90V0hCMS1sSDR4N2hwSDlqRzQ2M0ExRTBYRFZFMTc4aTNJTUFHZFItdTE4aWVfbVdVZm9lZklhanBfLXdYdUNwcExYejRETDBMNTJtanZCUHF5RUxqekRwcWhqQkRiSUEzMDNOR2V1V1RkNWd2SUVlZHB2Tmw2UDVkQTJza3RaVzFqMXlUaHBmS1RCWktCUjhzNHk3YXJiV2tkQWJxR0g0anU1dXlhWA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Stock: Assessing The 2026 Upside For Icotrokinra And Rusfertide (PTGX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPXzJ6SXdpZDIzdjBTaTRVTldrcDFiWlp1RHdoTGpHQmJsRUVwc1dUQWhCWER0T0RkY1g1Z0tGT1BySE01am9iT1RINHN4UHprOFVIMEg5TERkRkl1ZEo5OFVPZ0FSSkRhRnRReTZhYm9wamw0dlc5RWd5Wk9VUFdWaTBLUURWNkl0aXA5T2ZpZFpmV3RNd0ZyY3RORE92bHBPcGZMQ2E3Z1BwZlNDUXVZUEVSSkVXaTQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQVDkyY190ZG1zTWlKa3N3UVAwbUVma19iZ2RSVjE4ZzZWRGEwZXF5WDNXWVgxTURic0JVbkpVWThibkExOERPa1lycVJqQUtYaUdXMm9kMk13THktc21DZ0NqVExsdXh5WEpIMUtkeWRPTzdPOFBZOWZUQm9EbWRXNmoxQ0xzdmNuUkJ2SVJaUWVOUQ?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-11T07:00:00+00:00", "published_display": "11 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com", "summary": "Protagonist Therapeutics (PTGX) stock reached an all-time high of $141.79, currently trading at $143.26 with a market capitalization of $9.06 billion. The company has seen significant growth, with a 155.18% increase over the past year and a 61% year-to-date return, driven by posi", "url": "https://ca.investing.com/news/stock-market-news/protagonist-therapeutics-stock-hits-alltime-high-at-14179-usd-93CH-4742066", "source_name": "Investing.com Canada", "published_at": "2026-07-20T13:39:44", "published_display": "20 Jul 2026 13:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Barclays 28th Annual Global Healthcare Conference summary", "summary": "Protagonist Therapeutics (PTGX) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting its focus on novel peptide therapeutics and its two lead assets, icotrokinra and rusfertide. Icotrokinra, an oral IL-23 blocker, targets psoriasis, while rusfertide, a", "url": "https://quartr.com/events/protagonist-therapeutics-ptgx-barclays-28th-annual-global-healthcare-conference_FLI9Rqt9", "source_name": "Quartr", "published_at": "2026-07-20T10:39:44", "published_display": "20 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Rises In Biotech Rally While Valuation Keeps The Debate Open", "summary": "", "url": "https://news.google.com/rss/articles/CBMi9AFBVV95cUxQSEJPalhUcnk3SFRFT2pJeGdIUWxwS1hqdjhrTEJRaWZkelpLQ0Vqb2p1aFd4eXUzZVhGZGduOEt1OWtHY0VfU3BEMlFBdmU0UEMtcGNhZlZkeWZYVzBGTFpnSzhmTWtBak5QMkxmbm9GZW1KR2F2STAxcHJqNHhwUVVsX2ZWM1dDdjcxVVFVVDZIZldZVWJza2loM0VmVm5BYXJ6dnFCOXN4d0hTNHpvR1JJdFRqVHZYRThPbUJmV3c4bE0tWE5tTmRKNG5FVDZWWEFTbl9jX3JFVEU4bldtdUdzSTZndEV5M1pqQ1ktQUFraC1N0gH0AUFVX3lxTFBIQk9qWFRyeTdIVEVPakl4Z0hRbHBLWGp2OGtMQlFpZmR6WktDRWpvanVoV3h5dTNlWEZkZ244S3U5a0djRV9TcEQyUUF2ZTRQQy1wY2FmVmR5ZlhXMEZMWmdLOGZNa0FqTlAyTGZub0ZlbUpHYXZJMDFwcmo0eHBRVWxfZlYzV0N2NzFVUVVUNkhmV1lVYnNraWgzRWZWbkFhcnp2cUI5c3h3SFM0em9HUkl0VGpUdlhFOE9tQmZXdzhsTS1YTm1OZEo0bkVUNlZYQVNuX2NfckVURThuV211R3NJNmd0RXkzWmpDWS1BQWtoLU0?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-19T12:31:41+00:00", "published_display": "19 Jul 2026 12:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Jumps 5.7% Amid Sector-Wide Rally", "summary": "Protagonist Therapeutics saw its shares surge 5.7% on Friday, closing at $139.60, as the biotech company benefited from a broad sector-wide rally. This synchronized movement among biotechnology stocks suggests that macro factors and a shift in investor risk appetite, rather than ", "url": "https://news.alphastreet.com/protagonist-therapeutics-jumps-5-7-amid-sector-wide-rally/", "source_name": "AlphaStreet", "published_at": "2026-07-17T17:10:57", "published_display": "17 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Reports Granting of Inducement Awards", "summary": "Protagonist Therapeutics granted inducement awards to three new employees, consisting of options to purchase 12,600 shares and RSUs for 3,330 shares of common stock. These awards were made under its Amended and Restated Inducement Plan, with vesting periods of four years for both", "url": "https://finance.yahoo.com/healthcare/articles/protagonist-therapeutics-reports-granting-inducement-200500825.html", "source_name": "Market source", "published_at": "2026-07-17T11:09:52", "published_display": "17 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Citizens raises Protagonist Therapeutics price target on Icotyde uptake By Investing.com", "summary": "Citizens increased its price target for Protagonist Therapeutics (NASDAQ: PTGX) to $165 from $137, while maintaining a Market Outperform rating, due to better-than-expected prescription volume for its drug Icotyde. The firm now estimates approximately $8 million in second-quarter", "url": "https://ca.investing.com/news/stock-market-news/citizens-raises-protagonist-therapeutics-price-target-on-icotyde-uptake-93CH-4739233", "source_name": "Investing.com Canada", "published_at": "2026-07-17T09:58:20", "published_display": "17 Jul 2026 09:58", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Three New Hires Receive Protagonist Options and RSUs Under Inducement Plan", "summary": "Protagonist Therapeutics (Nasdaq: PTGX) granted equity inducement awards to three new employees on July 15, 2026. These awards include options for 12,600 shares and RSUs for 3,330 shares, with an option exercise price of $135.46. The awards were approved by the compensation commi", "url": "https://www.stocktitan.net/news/PTGX/protagonist-therapeutics-reports-granting-of-inducement-dcke3ikg6f1p.html", "source_name": "Stock Titan", "published_at": "2026-07-16T20:11:19", "published_display": "16 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Jumps 5.3% After Barclays Maintains Overweight", "summary": "Protagonist Therapeutics saw its shares jump 5.3% to $138.27 after Barclays maintained an Overweight rating and significantly raised its price target by 26.9% to $151. This upgrade reflects increasing confidence in the biotechnology company's prospects, driving keen investor inte", "url": "https://news.alphastreet.com/protagonist-therapeutics-jumps-5-3-after-barclays-maintains-overweight/", "source_name": "AlphaStreet", "published_at": "2026-07-16T10:39:59", "published_display": "16 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 94, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX Maintained by Barclays -- Price Target Raised to $151", "summary": "Barclays has maintained an \"Overweight\" rating for Protagonist Therapeutics (PTGX) and increased its price target from $119.00 to $151.00, signaling confidence in the company's biotech potential. While analysts are optimistic, GuruFocus indicates that PTGX is significantly overva", "url": "https://www.gurufocus.com/news/8957467/ptgx-maintained-by-barclays-price-target-raised-to-151", "source_name": "GuruFocus", "published_at": "2026-07-14T12:39:48", "published_display": "14 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) AGM 2026 Summary", "summary": "This article summarizes Protagonist Therapeutics' (PTGX) 2026 Annual General Meeting (AGM). Key topics included the election of directors, an advisory vote on executive compensation, ratification of the auditor (Ernst & Young), and approval of the 2026 equity incentive plan. The ", "url": "https://quartr.com/events/protagonist-therapeutics-inc-ptgx-agm-2026_FLI9TJSQ", "source_name": "Quartr", "published_at": "2026-07-11T09:12:12", "published_display": "11 Jul 2026 09:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Investor Update Summary", "summary": "Protagonist Therapeutics (PTGX) announced positive phase III VERIFY study results for Rusfertide in polycythemia vera, meeting primary and secondary endpoints with significant efficacy and improved patient-reported outcomes. The drug was well-tolerated with no new safety signals.", "url": "https://quartr.com/events/protagonist-therapeutics-inc-ptgx-investor-update_FLI94zCp", "source_name": "Quartr", "published_at": "2026-07-11T09:10:21", "published_display": "11 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary", "summary": "This article summarizes Protagonist Therapeutics' presentation at the Goldman Sachs 47th Annual Global Healthcare Conference in 2026. The company is transitioning to a commercial stage, anticipating approval for Rusfertide, and boasts a strong financial position due to product la", "url": "https://quartr.com/events/protagonist-therapeutics-inc-ptgx-goldman-sachs-47th-annual-global-healthcare-conference-20_FLI9TQMC", "source_name": "Quartr", "published_at": "2026-07-11T08:39:38", "published_display": "11 Jul 2026 08:39", "sentiment": "positive", "sentiment_pct": 93, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Icotyde\u2019s Launch and Rusfertide\u2019s Priority Review Change Protagonist Therapeutics\u2019 (PTGX) Narrative", "summary": "Protagonist Therapeutics (PTGX) has experienced a significant shift in its investment narrative due to the U.S. launch of its psoriasis drug Icotyde and the FDA priority review for its polycythemia vera candidate rusfertide, with an action date in August 2026. This marks a transi", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/will-icotydes-launch-and-rusfertides-priority-review-change", "source_name": "Simply Wall Street", "published_at": "2026-07-10T21:10:14", "published_display": "10 Jul 2026 21:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks Undervalued", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/protagonist-therapeutics-ptgx-icotyde-launch-141440105.html", "source_name": "Simply Wall St.", "published_at": "2026-07-09T14:14:40+00:00", "published_display": "09 Jul 2026 14:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority Review", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNjYyazduVzM5SzR4TkdoWVRfb1BnLWhVWFVfNC1DWGthNmZzNHczbjluZ0JKbmRHZGRXTFhsamxDaVR6c0dQa3FuWVFmZTludHkyMzEzMU5YSXhGSjV1WEFsOG1ERHY5RnBsQnVxN0dQLTlKNkFMMXFRSjlBVVRUVXEwZG5JUDRuekcydWFYNnp4S3VCMllxWGhkUkI2RVJDSFIxWHloSlV0QQ?oc=5", "source_name": "Market source", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Could Be 66% Below Fair Value As Pipeline Progress Lifts Interest", "summary": "Protagonist Therapeutics (PTGX) saw its stock climb 7.1% due to investor focus on key pipeline milestones and recent FDA activity related to rusfertide and Icotyde. Despite a P/B ratio of 13.7x, which is high compared to the broader US biotech sector, a discounted cash flow (DCF)", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/protagonist-therapeutics-ptgx-could-be-66-below-fair-value-a", "source_name": "Simply Wall Street", "published_at": "2026-07-09T07:41:46", "published_display": "09 Jul 2026 07:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Q1 2026 earnings summary", "summary": "Protagonist Therapeutics reported a strong Q1 2026 driven by FDA approval for ICOTYDE, triggering a $50M milestone payment, and a strategic opt-out of U.S. profit-sharing for rusfertide with Takeda, resulting in a $200M payment. The company achieved significant revenue growth and", "url": "https://quartr.com/events/protagonist-therapeutics-inc-ptgx-q1-2026_FLI9RqxP", "source_name": "Quartr", "published_at": "2026-07-08T20:10:21", "published_display": "08 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/protagonist-therapeutics-ptgx-12-5-161823936.html", "source_name": "Simply Wall St.", "published_at": "2026-07-08T16:18:23+00:00", "published_display": "08 Jul 2026 16:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?", "summary": "Protagonist Therapeutics (PTGX) stock saw a significant 7.1% rally, closing at $140.85, driven by investor confidence in its late-stage drug candidate rusfertide and expanding commercial opportunities for Icotyde. The FDA has accepted a new drug application for rusfertide with pr", "url": "https://finance.yahoo.com/markets/stocks/articles/protagonist-therapeutics-ptgx-surges-7-143000071.html", "source_name": "Market source", "published_at": "2026-07-08T10:30:00", "published_display": "08 Jul 2026 10:30", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist raises Protagonist Therapeutics stock price target on Icotyde outlook By Investing.com", "summary": "Truist Securities has increased its price target for Protagonist Therapeutics Inc. (NASDAQ: PTGX) to $145 from $121, maintaining a Buy rating, based on the strong commercial potential of its drug Icotyde. Johnson & Johnson, Protagonist's commercial partner, has highlighted Icotyd", "url": "https://ng.investing.com/news/stock-market-news/truist-raises-protagonist-therapeutics-stock-price-target-on-icotyde-outlook-93CH-2588523", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T19:42:01", "published_display": "07 Jul 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX Stock Grinds Higher As Pipeline Catalysts Build", "summary": "Protagonist Therapeutics (PTGX) stock rose over 7% following positive drug development news. The company launched ICOTYDE in the U.S. for psoriasis and has rusfertide under FDA priority review for polycythemia vera, alongside ongoing Phase 3 trials for ICOTYDE in other inflammato", "url": "https://stockstotrade.com/news/protagonist-therapeutics-inc-ptgx-news-2026_07_07/", "source_name": "StocksToTrade", "published_at": "2026-07-07T19:40:17", "published_display": "07 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics updates its clinical pipeline. PTGX focuses on peptide-based therapies", "summary": "Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical company focused on developing peptide-based therapies for inflammatory and hematologic diseases. The Nasdaq-listed company aims to advance its multi-program pipeline through clinical trials, differentiating its", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/protagonist-therapeutics-updates-its-clinical-pipeline-ptgx-focuses-on/69716334", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T17:11:28", "published_display": "07 Jul 2026 17:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Jumps 5.2% Amid Sector-Wide Rally", "summary": "Protagonist Therapeutics (PTGX) saw its shares rise by 5.2% on Tuesday, closing at $138.29, due to a broad rally across the biotechnology sector. This increase was part of a coordinated move, with several peer companies also experiencing similar gains, suggesting a sector-wide mo", "url": "https://news.alphastreet.com/protagonist-therapeutics-jumps-5-2-amid-sector-wide-rally/amp/", "source_name": "AlphaStreet", "published_at": "2026-07-07T16:40:17", "published_display": "07 Jul 2026 16:40", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?", "summary": "Protagonist Therapeutics (PTGX) stock has surged 64% in the last six months, driven by progress in its rare hematology candidate rusfertide, the commercial expansion of its immunology therapy Icotyde, and advancements in its pipeline assets. The FDA's priority review of rusfertid", "url": "https://www.tradingview.com/news/zacks:891a6064e094b:0-ptgx-stock-surges-64-in-six-months-what-is-driving-the-rally/", "source_name": "TradingView", "published_at": "2026-07-07T15:11:28", "published_display": "07 Jul 2026 15:11", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX Maintained by Truist Securities -- Price Target Raised to $145.00", "summary": "Truist Securities has reiterated a 'Buy' rating for Protagonist Therapeutics (PTGX), increasing the price target from $121.00 to $145.00, indicating optimism about its pipeline. Despite this, GuruFocus assesses PTGX as 114.6% overvalued with a GF Value\u2122 of $61.27, and its GF Scor", "url": "https://www.gurufocus.com/news/8947303/ptgx-maintained-by-truist-securities-price-target-raised-to-14500", "source_name": "GuruFocus", "published_at": "2026-07-07T13:11:28", "published_display": "07 Jul 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Protagonist Therapeutics, Inc. \u2013 NASDAQ:PTGX", "summary": "This article provides financial data for Protagonist Therapeutics, Inc. (NASDAQ: PTGX), specifically focusing on its forward price-to-sales ratio. It lists the company's ticker, stock market, and highlights its current financial and market status.", "url": "https://www.tradingview.com/symbols/NASDAQ-PTGX/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T11:11:28", "published_display": "07 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist Raises Price Target on Protagonist Therapeutics to $145 From $121, Keeps Buy Rating", "summary": "Truist has increased its price target for Protagonist Therapeutics (PTGX) to $145 from $121, while maintaining a Buy rating on the stock. This news follows the company's Q4 financial results where Unity Software (U.US) reported significant revenue growth, though the article seems", "url": "https://www.moomoo.com/news/post/72579388/truist-raises-price-target-on-protagonist-therapeutics-to-145-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-07T10:40:17", "published_display": "07 Jul 2026 10:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Truist raises Protagonist Therapeutics stock price target on Icotyde outlook", "summary": "Truist Securities has increased its price target for Protagonist Therapeutics (NASDAQ: PTGX) to $145 from $121, maintaining a Buy rating, based on the strong commercial outlook for its drug Icotyde in psoriasis treatment. Johnson & Johnson, Protagonist's commercial partner, proje", "url": "https://www.investing.com/news/analyst-ratings/truist-raises-protagonist-therapeutics-stock-price-target-on-icotyde-outlook-93CH-4778730", "source_name": "Investing.com", "published_at": "2026-07-07T06:52:00", "published_display": "07 Jul 2026 06:52", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Protagonist Therapeutics, Inc. \u2013 NASDAQ:PTGX", "summary": "This article provides financial information for Protagonist Therapeutics, Inc. (NASDAQ: PTGX), specifically focusing on its enterprise value to EBIT forward. It appears to be a stub or a data page from TradingView, displaying the current market status and various navigation optio", "url": "https://www.tradingview.com/symbols/NASDAQ-PTGX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T19:10:11", "published_display": "06 Jul 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Protagonist Therapeutics, Inc. \u2013 NASDAQ:PTGX", "summary": "The article provides the enterprise value to revenue forward for Protagonist Therapeutics, Inc. (NASDAQ: PTGX). It presents basic financial and market information for the company as listed on TradingView, covering its Nasdaq Stock Market data.", "url": "https://www.tradingview.com/symbols/NASDAQ-PTGX/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T15:43:23", "published_display": "06 Jul 2026 15:43", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Inc stock hits all-time high at 131.99 USD", "summary": "Protagonist Therapeutics Inc. (PTGX) stock has reached an all-time high of $131.99, currently trading at $132.27, showcasing a significant 163.93% increase over the past year. Despite analysts viewing the stock as overvalued, they predict profitability this year with forecasted e", "url": "https://www.investing.com/news/company-news/protagonist-therapeutics-inc-stock-hits-alltime-high-at-13199-usd-93CH-4776767", "source_name": "Investing.com", "published_at": "2026-07-06T14:43:23", "published_display": "06 Jul 2026 14:43", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Protagonist (NASDAQ: PTGX) trades 9,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPNGZ3ZTk3czJ2SlNOcDRReHpuOTZUOHdGLVQ0VWhCU1ZyMVNQLWtxdmJoMEp4cDBfRlhVbE9xdEhLbzlRLTVFVnBJS21PSGNLM05MUGxXb1hpRDQ4UmtTUVU5VHN3eV9EYkJneHA3X0VERWZPSl9xTFVRbUZTd210SDQtWGZGZDRvN2dqX3Z2aUJrbmgtVXhtZy01dms4SEtqNnVJWGJtMENQX0VPbTg0YjdETjVTdzZUYnNNQlZmbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-25T07:00:00+00:00", "published_display": "25 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PTGX (NASDAQ) insider 10b5-1 sale of 9,000 shares; option exercise noted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNa3JkT1dkTjBSMjhXMXNlS1VFdDgzQldyZ19HS0dMTDZrcDdkRzZ5bzZRX29qMUpZLWlHX3V5eEhaWVZFTTh4aFh1dl9uLTBKTnVmQk0zdGwyODdkXzJ6SVBYdEJYQTU4eDJBQjAxeExyRHpGTU1OSkZPZHhUTkxVbVFNZW0zTEdQM25STjYtR1JhLWZwSU9JZFFZMTJzbV91Z0Fhb2NVazg?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxQUUN6amt6WEcyZGZEX1lHZkF0SHF5bjZXQmc5TFhNQW05UjFrOUtuZmdpUmxqbDZCLVdFY09FOW1uSDluTkI5QzNvaV84MGxyRlJvZWNjMlQySkVRR1ZKSUNQcUpsUDQ4RkxxQUpNRWVzUklVamp3RFhERlVOX3Z2MHJrR2UxUEpseEhQRGxXNDI5eHA3T2Nyekh6MlhpRWVWcmZwWVltQlRsZW55d2t3S2NLNnY0SUFlT1R0T1FjY3duVG04eHhlcG1TS3htZ2lGMC02SDUyUHBLZDFUQ01oRlVGR25tcHRwMUstVlB6RdIB9AFBVV95cUxQWU1oakw3ZXJCRkNtbGpMWXIxQ2VibUt5T3MtX0lsc0ZOWWJ2SmtQS29xRHJBN21CYk5ibnVjQzB2V0pBLU54dTh6cHlfV2tGS2RCRWR5VVU4WWZRcjZidHdkZTBaZ1gyNElXbjh4TFZnSjdMZ09FVkxOaHNucThOblJTMXprSEFJWnhPbUJGWXk2X0QyU1NhZDZIQUcxX2dKd0dsVjQwNjljVUZHMFJMS0V6SDFhc1NhajB3eW55bHdIMTRZLUxNdmY4M2hSZE1tbWtKZkdOQlM1aENyOV9DOVNSZDNnUDZXS3NQcTYzeHFZSGo5?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics(PTGX.US) Officer Sells US$7.51 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOcGtaYVlZSGVIX2RCNHQ1VTdEazZqYXd0Mjh4cl9ZR0VaYkpSbUM4VEdSTDVaSjh4cDIzbDgweVQxTHMwWmRkNnpyMTAwZWhsbW02bTJjRFhjVWFDZ0FTb29udWstR2pyYlZnS1czdkVsaUdHbXBCQmpaQTNZckNqQngzTURtNXd3al9kMy1XNnQzM29QZHUzQUNZekJ4Q3JidFJiWFJGbGVlUQ?oc=5", "source_name": "Moomoo", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analyst Forecasts For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Are Surging Higher", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPTnhibVJ6MElyTnljYk10VUV4ZU1iR0xNdXgtd2oxV3FRc3dVSnJCSVNlZURQYTZQZFRDWFhCcnFleWpkdTV3NW54bVFzNWkyUnFXZXJLbWptMXdTS1ZTZVlnaTlpX3RiWk5senB4WmZRaERTR21odGdUejU5WVdORy1YZnBuck13SUh3clFMQjMyOVg3djVGbm55UlNzVElQNERIdjJra0FoX000R1Z1aw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxQZ3pXQWJuY05fWkkyWms5bHNrU3l4MklmTFRIeUQ2UWl5UWk4ZTBWN1lOTGFkd0lEb0hURGpnY20yNk01SnY0bmlVZVFlTHlEelVSNG1ZZE81eTE5VDBEVkg3UGtDOHhmTDk4UUppN253cG5uaWVQLU9QSkx3eWJZYWdOY3VXTEM5NkN0RUFjZGJabEJPU1dqbThMeV9qOE0wWWJHTzJMRm9BM0xpN0ZGSE1OS28tZ05raWZGcWE0Q2xFNXdVRnZlUnVvOHU4am1STncwWHVqSGRlSDE1LTZZWkZBWi1DZmRpdVk2MHFB?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 141% One Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxPVTB4T19JMS1rejZnbnl5ODVtcEMxR1hwVXlBclUzalk4TGNBQU82bGR5eUNMOWYxS2ltM0RDeFRBWnR6MFZwdjEzQ0dHSUdNajMtN0IzUEJtZWNKdk1rOS1SMEpGYmt6czFIeE5DNUtPWVhWSnBrYTdQaURFQjZ3R20wbElLVlhfa0x2SUJGY2FUZ0VqRTNtbjNFQ1FwTF9kLVpuZVdldlAxWmc?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Inc. (PTGX): Billionaire Tom Steyer Likes Upside Potential of This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxPa1BaaC1wWk5TZFF4WC1jNi1RdXNfOTVJdkdNbXd4Y2xFejVmYnBZTnhWOVdIa0FwOVRObnBKZE1TMGJURmxOQmNxTVFiZkpHRXhrNHBYQlE2Z29CSFBYaVVQVFJ3aU5YbW5Pdk5ya1ZoZUtnMzlTWjRuSlRzWHpJelpxbU9UWGlyaUhfZDF4WDVWQm1kTVFPMzJrZ1lPQzk4M00wOTEwdHhfMUJaWW5Z?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda takes U.S. rights to rusfertide; Protagonist eligible for $475M", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOTUJlTjRJOEFheWVVNkR3QXFXTzNRREtGRkFUUzNtSDk0eTFsTC1wM0Y0Sk1iN0ppTFJWcTNzbWxCMTRMZXl3MG1ma3FxX3BTLWFUb0VjazRlbXR6NUVPVjZlOU42anpRWUFtNXJzWmZJdV8xcDRTWlBNMi1fXzFXSGhSbUh6T1BfLWNJMkxCZ0dXVzN6TlU0UGdBTWtPOU1ITldCblBoaWwxeF96QjJrN1FzS3pVZXI3U1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Inc. (PTGX): Billionaire Joe Edelman Likes This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPTmotR3lfS2V6WEtvWFdwR3RWTG54SHdkUUN6Z0d2VXdfV2JHZEplV2dwT1JteHJVUWJmb1htNDkyamxJNDZOQ3dPX2JoNldSQjJMWV9nMkFFbi1QV3pTMjBiamJwN1JMZ1JrMTItdzZDdGZKYWlGTmc4RmpTZGhhREZfYXpBVzh3NzNIMWdSRUJKc29hTGwtMEZ4dFJCYnR3OS1QMWJmOUw0VnFBRzdrUG9wZlM?oc=5", "source_name": "Market source", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Protagonist Therapeutics (PTGX) After A 129% One Year Surge?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two new hires get rights to 69,850 Protagonist shares in awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNVVBZNEdZeTdIc2NwdTVRbkhZRF9JM0tteG5WcGpkSFdEOE1UbW1pUEV0MXpRZHJHd2s2VTRXNmg4R19hNlgtYmhLNTkzRXhmazNMeXppUWxtUHl0U1lLYzlwc0FZdG00eWhXbVR5WC1CVzRZeG1wWmR5TzVMWFlqRFBMS2UtZ1dPcHREb1o0NTNwUjIyeVlmbnd3TGlfTjNwUUtNZ3JvOUo3NnpiNHZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-16T07:00:00+00:00", "published_display": "16 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPbE5JMFA0WndobVlVZXBUanhGT3ZmdmNzdW1SZ0FSOFM5UXdhN1M4WlJpTk4wMFNmMFRyVm5QQnVySHAweWhMZUFOOHFGUGJuaGFLTTNobjNYTlNSUHN3UFNqaEhoRWhwcHZrNUxjWWFTVFFNeHBseEdxVFhFMGFuN0ZPNy02akFRODU0MlFEcEtNeXB4SXpKbml2SjNyUDMxWHZSTg?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics Stock Rallies Nearly 7% in a Week: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQd0JMT0FRRWs0bFM2aXRmU0ZOQnZNNEJTdS1QTUNEbmd6RUc0a1pkcGtSSE5nN1FQSFZlTHZCZDkzSjZqeFN3cXRTTU5Gd1EzUk9NSXVFTlROVjB4ZlpzdnZQLWlkbU16cFVrSXl3Ynd1anR6cUFsR2NMaVhXSkpNMW56UnM5dnR4ZXE2MC00emhYNU9nbHhiX0Jibk0wdmRnemNmY3M2ZnVmZXFKOF93?oc=5", "source_name": "Market source", "published_at": "2026-03-20T07:00:00+00:00", "published_display": "20 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA approves first oral IL-23 psoriasis pill, Protagonist lands $50M", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOZk5kZ19ZbDZ3bHhrWF90V0hCMS1sSDR4N2hwSDlqRzQ2M0ExRTBYRFZFMTc4aTNJTUFHZFItdTE4aWVfbVdVZm9lZklhanBfLXdYdUNwcExYejRETDBMNTJtanZCUHF5RUxqekRwcWhqQkRiSUEzMDNOR2V1V1RkNWd2SUVlZHB2Tmw2UDVkQTJza3RaVzFqMXlUaHBmS1RCWktCUjhzNHk3YXJiV2tkQWJxR0g0anU1dXlhWA?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Stock: Assessing The 2026 Upside For Icotrokinra And Rusfertide (PTGX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPXzJ6SXdpZDIzdjBTaTRVTldrcDFiWlp1RHdoTGpHQmJsRUVwc1dUQWhCWER0T0RkY1g1Z0tGT1BySE01am9iT1RINHN4UHprOFVIMEg5TERkRkl1ZEo5OFVPZ0FSSkRhRnRReTZhYm9wamw0dlc5RWd5Wk9VUFdWaTBLUURWNkl0aXA5T2ZpZFpmV3RNd0ZyY3RORE92bHBPcGZMQ2E3Z1BwZlNDUXVZUEVSSkVXaTQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-30T08:00:00+00:00", "published_display": "30 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Protagonist Therapeutics (PTGX) After Its 119% One-Year Surge?", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgFBVV95cUxQVDkyY190ZG1zTWlKa3N3UVAwbUVma19iZ2RSVjE4ZzZWRGEwZXF5WDNXWVgxTURic0JVbkpVWThibkExOERPa1lycVJqQUtYaUdXMm9kMk13THktc21DZ0NqVExsdXh5WEpIMUtkeWRPTzdPOFBZOWZUQm9EbWRXNmoxQ0xzdmNuUkJ2SVJaUWVOUQ?oc=5", "source_name": "Market source", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) 51% Price Boost Is Out Of Tune With Revenues", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-11T07:00:00+00:00", "published_display": "11 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 59, "sentiment_summary": {"positive": 28, "negative": 1, "neutral": 30, "score": 63, "total": 59, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 18.5, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 28, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 140.91, "latest_week": "2026-07-17", "one_week_move": 7.2, "four_week_move": 24.9, "twelve_week_move": 40.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.626978, "market_dynamics_buy_signal": false, "relative_strength": 46.133058, "fair_value_gap": 170.3, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.4502, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+7.2% over one week, +24.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 74, "badges": ["Sentiment confirms active trend", "Positive but stretched"], "opportunities": ["Constructive tone aligns with the Sharemaestro trend signal."], "risks": ["Constructive tone is arriving with price materially above fair value."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "simplywall.st", "count": 8}, {"label": "Stock Titan", "count": 6}, {"label": "Quartr", "count": 5}, {"label": "TradingView", "count": 5}, {"label": "AlphaStreet", "count": 3}, {"label": "Investing.com Canada", "count": 2}, {"label": "GuruFocus", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 8}, {"label": "Regulatory and legal", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "63/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+7.2% over one week, +24.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Protagonist Therapeutics stock hits all-time high at 141.79 USD By Investing.com"}], "updated_at": "2026-07-21T00:24:52.094081+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}